While there is a shortage of testing kits, manpower and capacities, India does not have other scalable testing options.
'This government did not have any plan for safety stocks of essential medicines.'
When compared to the domestic sales of April 2019, the growth is around 37 per cent. However, compared to the previous month (March), the growth is 18.4 per cent.
Artificial shortages and brazen hawking of the drug on the streets at 15 times the normal price rule the day as the official machinery tries desperately to stamp out the parallel market, reports Sohini Das
Delhi, which has been one of the worst affected states, accounted for less than two per cent of total vaccinations in the 18-44 age-group.
Initial data has shown immunity triggered by the two mRNA vaccines -- Pfizer-BioNTech and Moderna -- lasts for at least six months
While the Indian government has been procuring Covid-19 vaccines at low prices so far, manufacturers have to declare the prices of vaccines they would supply to the open market (industries, private hospitals, etc) and state governments before May 1. Sohini Das reports.
Sputnik V is already approved in India and Sinovac is unlikely to come in as it does not meet the criteria.
The second wave of the pandemic has not only crippled medical infrastructure in terms of hospital beds, but has also led to bottlenecks in invasive ventilators and medical oxygen capacities and supplies.
One challenge for many laboratories in ramping up is the shortage of trained manpower for collecting samples, report Sohini Das, Vinay Umarji and Virendra Singh Rawat.
'In case of shortage of other raw material, like filters and bags, one can try to develop another vendor. However, for chemicals as critical as adjuvants, this is not possible'
This will be an upfront payment for the vaccine doses that these two companies will supply to the government.
'Our automakers export 50 per cent of what they manufacture and once the policy comes into play, which is in the next 2-3 years, we would become a Rs 10 trillion industry.'
'We completed Rs 17 trillion worth of projects in the first term and currently Rs 9 trillion worth of contracts are under construction.'
'The US has invoked the Defence Act and banned export of raw materials.' 'This is as good as banning vaccines.'
The production of Covaxin will increase from the current 10 million doses per month to 60 million-70 million by July-August.
It has taken 51 days to reach a daily caseload of 84,000 from 11,000, as against 85 days taken in the first wave, report Abhishek Waghmare and Sohini Das.
While the government has not barred procurement of equipment from Chinese companies, the process to amend the general financial rules (GFR) 2017 has started. This will impose restrictions on bidders in public procurement from countries that share a land border with India, reports Megha Manchanda.
'I don't think anybody would want to be in my position today where every head of State has to be explained that I am prioritising my country because there is a surge in cases.'
Both manufacturers have sought funds in excess of Rs 150 crore under the department of biotechnology's Mission Covid Suraksha scheme. Announced last November, the scheme has an outlay of Rs 900 crore to help develop Covid vaccines, from the clinical development stage to setting up production sites.
© 2025 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances